Translational Stroke Research

, Volume 7, Issue 4, pp 343–353 | Cite as

Academic-industry Collaborations in Translational Stroke Research

  • Johannes Boltze
  • Daniel-Christoph Wagner
  • Henryk Barthel
  • Matthew J. Gounis
SI: Challenges and Controversies in Translational Stroke Research

Abstract

Academic-industry collaborations are an emerging format of translational stroke research. Next to classic contract research models, a multitude of collaboration models has been developed, some of which even allowing for multinational or intercontinental research programs. This development has recently been paralleled by first successful attempts to overcome the translational stroke research road block, such as the unprecedented success of novel endovascular approaches or the advent of the multicenter preclinical trial concept. While the first underlines the role of the industry as a major innovation driver in stroke research, the latter will require enrollment of industrial partners for optimal output. Moreover, academic-industry partnerships are invaluable to bridge the translational “valley of death” as well as funding gaps in times of dwindling public funding and declining high risk capital investments. However, these collaborations are also subject to relevant challenges because interests, values, and aims often significantly differ between cademia and industry. Here, we describe common academic-industry collaboration models as well as associated benefits and challenges in the stroke research arena. We also suggest strategies for improved planning, implementation, guidance, and utilization of academic-industry collaborations to the maximum mutual benefit.

Keywords

Academic-industry collaboration Stroke research Translational research Research alliances 

Notes

Acknowledgments

We thank Professor Charli Kruse for providing input and valuable perspectives on academic-industry collaborations. Illustrative elements in Figure 1 were either taken from inhouse material or purchased from the fotolia webpage (rodent pictures only, www.fotolia.com).

Author contribution

JB, DCW, and MJG wrote the manuscript. All authors corrected and improved the draft, and approved the final manuscript version.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Funding

Only institutional funds were used for this project.

References

  1. 1.
    George PM, Steinberg GK. Novel stroke therapeutics: unraveling stroke pathophysiology and its impact on clinical treatments. Neuron. 2015;87(2):297–309.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, et al. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383(9913):245–54.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Matchar DB, Nguyen HV, Tian Y. Bundled payment and care of acute stroke: what does it take to make it work? Stroke. 2015;46(5):1414–21.CrossRefPubMedGoogle Scholar
  4. 4.
    Auriel E, Bornstein NM. Neuroprotection in acute ischemic stroke—current status. J Cell Mol Med. 2010;14(9):2200–2.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Gladstone DJ, Black SE, Hakim AM. Heart and Stroke Foundation of Ontario Centre of Excellence in stroke recovery. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke. 2002;33(8):2123–36.CrossRefPubMedGoogle Scholar
  6. 6.
    Pendlebury ST. Worldwide under-funding of stroke research. Int J Stroke. 2007;2(2):80–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372(24):2296–306.CrossRefPubMedGoogle Scholar
  8. 8.
    Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372(1):11–20.CrossRefPubMedGoogle Scholar
  9. 9.
    Campbell BC, Donnan GA, Lees KR, Hacke W, Khatri P, Hill MD, et al. Endovascular stent thrombectomy: the new standard of care for large vessel ischaemic stroke. Lancet Neurol. 2015;14(8):846–54.CrossRefPubMedGoogle Scholar
  10. 10.
    Amar AP, Griffin JH, Zlokovic BV. Combined neurothrombectomy or thrombolysis with adjunctive delivery of 3K3A-activated protein C in acute ischemic stroke. Front Cell Neurosci. 2015;9:344.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Martin JB. Academic-industrial collaboration: the good, the bad, and the ugly. Trans Am Clin Climatol Assoc. 2002;113:227–40.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Borsody MK, Yamada C, Bielawski D, Heaton T, Castro Prado F, et al. Effects of noninvasive facial nerve stimulation in the dog middle cerebral artery occlusion model of ischemic stroke. Stroke. 2014;45(4):1102–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Macleod MR, van der Worp HB, Sena ES, Howells DW, Dirnagl U, Donnan GA. Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke. 2008;39(10):2824–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Boltze J, Lukomska B, Jolkkonen J. MEMS–IRBI consortium. Mesenchymal stromal cells in stroke: improvement of motor recovery or functional compensation? J Cereb Blood Flow Metab. 2014;34(8):1420–1.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Hess DC, Sila CA, Furlan AJ, Wechsler LR, Switzer JA, Mays RW. A double-blind placebo-controlled clinical evaluation of MultiStem for the treatment of ischemic stroke. Int J Stroke. 2014;9(3):381–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Terpolilli NA, Kim SW, Thal SC, Kataoka H, Zeisig V, Nitzsche B, et al. Inhalation of nitric oxide prevents ischemic brain damage in experimental stroke by selective dilatation of collateral arterioles. Circ Res. 2012;110(5):727–38.CrossRefPubMedGoogle Scholar
  17. 17.
    Borsody MK, Yamada C, Bielawski D, Heaton T, Lyeth B, Garcia A, et al. Effect of pulsed magnetic stimulation of the facial nerve on cerebral blood flow. Brain Res. 2013;1528:58–67.CrossRefPubMedGoogle Scholar
  18. 18.
    Yoo AJ, Verduzco LA, Schaefer PW, Hirsch JA, Rabinov JD, González RG. MRI-based selection for intra-arterial stroke therapy: value of pretreatment diffusion-weighted imaging lesion volume in selecting patients with acute stroke who will benefit from early recanalization. Stroke. 2009;40(6):2046–54.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Campbell BC, Purushotham A, Christensen S, Desmond PM, Nagakane Y, Parsons MW, et al. The infarct core is well represented by the acute diffusion lesion: sustained reversal is infrequent. J Cereb Blood Flow Metab. 2012;32(1):50–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Wheeler HM, Mlynash M, Inoue M, Tipirneni A, Liggins J, Zaharchuk G, et al. Early diffusion-weighted imaging and perfusion-weighted imaging lesion volumes forecast final infarct size in DEFUSE 2. Stroke. 2013;44(3):681–5.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Ding G, Zhang Z, Chopp M, Li L, Zhang L, Li Q, et al. MRI evaluation of BBB disruption after adjuvant AcSDKP treatment of stroke with tPA in rat. Neuroscience. 2014;271:1–8.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Arnberg F, Grafstrom J, Lundberg J, Nikkhou-Aski S, Little P, Damberg P, et al. Imaging of a clinically relevant stroke model: glucose hypermetabolism revisited. Stroke. 2015;46(3):835–42.CrossRefPubMedGoogle Scholar
  23. 23.
    Ay I, Blasi F, Rietz TA, Rotile NJ, Kura S, Brownell AL, et al. In vivo molecular imaging of thrombosis and thrombolysis using a fibrin-binding positron emission tomographic probe. Circ Cardiovasc Imaging. 2014;7(4):697–705.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Weber RA, Hui ES, Jensen JH, Nie X, Falangola MF, Helpern JA, et al. Diffusional kurtosis and diffusion tensor imaging reveal different time-sensitive stroke-induced microstructural changes. Stroke. 2015;46(2):545–50.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Endres M, Engelhardt B, Koistinaho J, Lindvall O, Meairs S, Mohr JP, et al. Improving outcome after stroke: overcoming the translational roadblock. Cerebrovasc Dis. 2008;25(3):268–78.CrossRefPubMedGoogle Scholar
  26. 26.
    Kimmelman J, Mogil JS, Dirnagl U. Distinguishing between exploratory and confirmatory preclinical research will improve translation. PLoS Biol. 2014;12(5), e1001863.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Dirnagl U, Hakim A, Macleod M, Fisher M, Howells D, Alan SM, et al. A concerted appeal for international cooperation in preclinical stroke research. Stroke. 2013;44(6):1754–60.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Dirnagl U, Fisher M. International, multicenter randomized preclinical trials in translational stroke research: it’s time to act. J Cereb Blood Flow Metab. 2012;32(6):933–5.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Howells DW, Porritt MJ, Rewell SS, O’Collins V, Sena ES, van der Worp HB, et al. Different strokes for different folks: the rich diversity of animal models of focal cerebral ischemia. J Cereb Blood Flow Metab. 2010;30(8):1412–31.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Rewell SS, Fernandez JA, Cox SF, Spratt NJ, Hogan L, Aleksoska E, et al. Inducing stroke in aged, hypertensive, diabetic rats. J Cereb Blood Flow Metab. 2010;30(4):729–33.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Buga AM, Di Napoli M, Popa-Wagner A. Preclinical models of stroke in aged animals with or without comorbidities: role of neuroinflammation. Biogerontology. 2013;14(6):651–62.CrossRefPubMedGoogle Scholar
  32. 32.
    Quillinan N, Deng G, Grewal H, Herson PS. Androgens and stroke: good, bad or indifferent? Exp Neurol. 2014;259:10–5.CrossRefPubMedGoogle Scholar
  33. 33.
    Cai B, Wang N. Large animal stroke models vs. Rodent stroke models, pros and cons, and combination? Acta Neurochir Suppl. 2016;121:77–81.PubMedGoogle Scholar
  34. 34.
    Boltze J, Ayata C, Wagner DC, Plesnila N. Preclinical phase III trials in translational stroke research: call for collective design of framework and guidelines. Stroke. 2014;45(2):357.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Boltze J, Wagner DC, Henninger N, Plesnila N, Ayata C. Preclinical phase III trials in translational stroke research: community response on framework and guidelines. Transl Stroke Res. 2016. doi: 10.1007/s12975-016-0474-6.
  36. 36.
    Sandercock P. Negative results: why do they need to be published? Int J Stroke. 2012;7(1):32–3.CrossRefPubMedGoogle Scholar
  37. 37.
    Feuerstein GZ, Chavez J. Translational medicine for stroke drug discovery: the pharmaceutical industry perspective. Stroke. 2009;40(3 Suppl):S121–5.CrossRefPubMedGoogle Scholar
  38. 38.
    Carpenter Jr WT, Koenig JI, Bilbe G, Bischoff S. At issue: a model for academic/industry collaboration. Schizophr Bull. 2004;30(4):997–1004.CrossRefPubMedGoogle Scholar
  39. 39.
    Wang L, Plump A, Ringel M. Racing to define pharmaceutical R&D external innovation models. Drug Discov Today. 2015;20(3):361–70.CrossRefPubMedGoogle Scholar
  40. 40.
    Hodson R. Open innovation. Nature. 2016;533(7602):S53.CrossRefPubMedGoogle Scholar
  41. 41.
    Frei P, Dev KK. Drug dealers: $20 trillion of in-licensing payments. Drug Discov Today. 2013;18(21–22):1027–9.CrossRefPubMedGoogle Scholar
  42. 42.
    Comanor WS, Scherer FM. Mergers and innovation in the pharmaceutical industry. J Health Econ. 2013;32(1):106–13.CrossRefPubMedGoogle Scholar
  43. 43.
    Wong TY. How to bridge the “valley of death” between a research discovery and clinical application? Ann Acad Med Singapore. 2014;43(8):422–4.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Johannes Boltze
    • 1
    • 2
  • Daniel-Christoph Wagner
    • 2
  • Henryk Barthel
    • 3
  • Matthew J. Gounis
    • 4
  1. 1.Fraunhofer Research Institution for Marine Biotechnology and Institute for Medical and Marine BiotechnologyUniversity of LübeckLübeckGermany
  2. 2.Fraunhofer Institute for Cell Therapy and ImmunologyLeipzigGermany
  3. 3.Department of Nuclear MedicineUniversity of LeipzigLeipzigGermany
  4. 4.New England Center for Stroke Research, Department of RadiologyUniversity of Massachusetts Medical SchoolWorcesterUSA

Personalised recommendations